are looking at
Leukaemia, which may be acute or chronic, is a cancer that originates in blood-forming tissue such as the bone marrow, leading to the over-production of abnormal white blood cells. These abnormal cells accumulate more quickly in acute leukaemia, which is more aggressive than chronic leukaemia.
Lymphocytes and myeloid cells are the two main white blood cell types affected in leukaemia, leading to four leukaemia manifestations including acute myeloid leukaemia (AML), acute lymphocytic leukaemia (ALL), chronic myeloid leukaemia (CML) and chronic lymphocytic leukaemia (CLL). Symptoms vary depending on subtype and can include weakness, increased rates of infection and general feeling of illness.
Diagnosis may involve blood testing, bone marrow biopsy, spinal tap and imaging tests (for example, CT, MRI and PET scans). The subsequent treatment will depend on the type of leukaemia and how far it has spread. Treatments may include radiation therapy, chemotherapy, biologic therapy, immunotherapy, targeted therapy and haematopoietic stem cell transplantation.
Related news and insights
Daiichi Sankyo announced that the FDA has extended the review period for the New Drug Application (NDA) of quizartinib in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and as continuation monotherapy following consolidation, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3-ITD positive
Astellas Pharma Inc. and the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) announced topline results from the Phase III MORPHO clinical trial evaluating gilteritinib as a maintenance therapy following allogeneic hematopoietic stem cell transplantation (HSCT) for patients with FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) mutated acute myeloid leukemia (AML).
Servier, a global pharmaceutical company,announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting a marketing authorization for Tibsovo® (ivosidenib tablets) - an inhibitor of the mutated isocitrate dehydrogenase-1 (IDH1) enzyme - for two indications: i. in combination with azacitidine, for the treatment of adult patients with newly diagnosed IDH1-mutated Acute Myeloid Leukemia and not eligible for standard induction chemotherapy, ii. in monotherapy, for the treatment of adult patients with locally advanced or metastatic IDH1-mutated Cholangiocarcinoma, previously treated by at least one prior line of systemic therapy.
This guideline covers the planning and management of end of life and palliative care in for infants, children and young people (aged 0-17 years) with life-limiting conditions. It aims to involve children, young people and their families...
The estimated overall incidence of acute lymphoblastic leukaemia and lymphoblastic lymphoma in Europe is 1.28 per 1 000 000 individuals annually, with significant age-related variations.
In order to complement the already available European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with malignant lymphomas, ESMO organised a consensus conference...